ATE540681T1 - Verfahren zur behandlung von atherosklerose - Google Patents
Verfahren zur behandlung von atheroskleroseInfo
- Publication number
- ATE540681T1 ATE540681T1 AT07796488T AT07796488T ATE540681T1 AT E540681 T1 ATE540681 T1 AT E540681T1 AT 07796488 T AT07796488 T AT 07796488T AT 07796488 T AT07796488 T AT 07796488T AT E540681 T1 ATE540681 T1 AT E540681T1
- Authority
- AT
- Austria
- Prior art keywords
- treating atherosclerosis
- thrombosis
- cholesterol
- inflammation
- accumulation
- Prior art date
Links
- 201000001320 Atherosclerosis Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 101001130226 Homo sapiens Phosphatidylcholine-sterol acyltransferase Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 102100031538 Phosphatidylcholine-sterol acyltransferase Human genes 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81641506P | 2006-06-26 | 2006-06-26 | |
| PCT/US2007/014873 WO2008002591A2 (en) | 2006-06-26 | 2007-06-26 | Methods for treating atherosclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE540681T1 true ATE540681T1 (de) | 2012-01-15 |
Family
ID=38786909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07796488T ATE540681T1 (de) | 2006-06-26 | 2007-06-26 | Verfahren zur behandlung von atherosklerose |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20080096900A1 (de) |
| EP (2) | EP2037928B1 (de) |
| AT (1) | ATE540681T1 (de) |
| AU (1) | AU2007265475B2 (de) |
| CA (2) | CA2787343C (de) |
| ES (1) | ES2376396T3 (de) |
| WO (1) | WO2008002591A2 (de) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
| SI2489731T1 (sl) * | 2007-07-26 | 2014-12-31 | Amgen Inc. Patent Operations, M/S 28-2-C | Modificirani encimi lecitin-holesterol aciltransferaze |
| WO2010029552A1 (en) * | 2008-09-10 | 2010-03-18 | Transpharma Medical Ltd. | Transdermal delivery of oligosaccharides |
| CN102802659B (zh) * | 2009-06-12 | 2015-11-25 | 阿尔法科制药有限责任公司 | Lcat治疗贫血和红细胞功能障碍的用途 |
| WO2011081667A1 (en) * | 2009-12-31 | 2011-07-07 | Immunitor USA, Inc. | Composition for atherosclerosis, obesity and obesity-related disorders |
| BR112012028462A2 (pt) | 2010-05-06 | 2016-07-19 | Alphacore Pharma Llc | liberação de éster de colesterol para tecidos esteroidogênicos |
| PH12013500301A1 (en) * | 2010-08-16 | 2013-03-25 | Boehringer Ingelheim Int | Oxadiazole inhibitors of leukotriene production |
| WO2012027322A1 (en) | 2010-08-26 | 2012-03-01 | Boehringer Ingelheim International Gmbh | Oxadiazole inhibitors of leukotriene production |
| EA201300389A1 (ru) | 2010-09-23 | 2013-09-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Оксадиазольные ингибиторы продуцирования лейкотриена |
| EP2619196B1 (de) | 2010-09-23 | 2015-09-16 | Boehringer Ingelheim International GmbH | Oxadiazolhemmer der leukotrienproduktion |
| WO2013086443A1 (en) | 2011-12-08 | 2013-06-13 | Amgen Inc. | Agonistic human lcat antigen binding proteins and their use in therapy |
| AR089853A1 (es) | 2012-02-01 | 2014-09-24 | Boehringer Ingelheim Int | Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso |
| ES2563861T3 (es) | 2012-06-14 | 2016-03-16 | Daiichi Sankyo Company, Limited | Derivado de piperidinilpirazolopiridina |
| WO2015050148A1 (ja) * | 2013-10-04 | 2015-04-09 | 第一三共株式会社 | 3-アリールピラゾロピリジン誘導体 |
| KR20160096612A (ko) * | 2013-12-13 | 2016-08-16 | 다이이찌 산쿄 가부시키가이샤 | 5-하이드록시-4-(트리플루오로메틸)피라졸로피리딘 유도체 |
| WO2015087996A1 (ja) * | 2013-12-13 | 2015-06-18 | 第一三共株式会社 | イミダゾピリジン誘導体 |
| WO2015111545A1 (ja) * | 2014-01-21 | 2015-07-30 | 第一三共株式会社 | 縮合ピラゾール誘導体 |
| TWI713534B (zh) | 2015-06-11 | 2020-12-21 | 日商第一三共股份有限公司 | 5-羥基-4-(三氟甲基)吡唑并吡啶衍生物之結晶及其用途 |
| EP3490579B1 (de) | 2016-07-27 | 2025-09-10 | Hartis-Pharma SA | Kombinationstherapie zur behandlung von sichelzellanämie und wiederherstellung von rbc-funktionen |
| WO2019100086A2 (en) * | 2017-11-15 | 2019-05-23 | Parodi Juan C | System for optimal hydration |
| KR20200138202A (ko) | 2018-03-30 | 2020-12-09 | 다이이찌 산쿄 가부시키가이샤 | Lcat 결손증 치료약 |
| LT4115879T (lt) * | 2019-07-31 | 2026-01-26 | Intas Pharmaceuticals Ltd. | Farmacinė kompozicija, apimanti hmg-coa reduktazės inhibitorius ir fenofibratą |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
| CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
| US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
| CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
| US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
| US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
| EP0206448B1 (de) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hämoglobin, das an ein Poly(alkenylenoxid) gebunden ist |
| JPS63167409A (ja) | 1986-12-27 | 1988-07-11 | Yamaha Corp | 磁気記録体 |
| US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4925673A (en) | 1986-08-18 | 1990-05-15 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids |
| US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
| ATE186724T1 (de) | 1987-09-04 | 1999-12-15 | Beecham Group Plc | Substituierte thiazolidindionderivate |
| US6288095B1 (en) | 1987-09-04 | 2001-09-11 | Beecham Group P.L.C. | Compounds |
| DE3889853D1 (de) | 1987-11-05 | 1994-07-07 | Hybritech Inc | Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik. |
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| JP3507486B2 (ja) | 1991-03-15 | 2004-03-15 | アムジエン・インコーポレーテツド | 顆粒球コロニー刺激因子の肺内投与 |
| HU9203780D0 (en) | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
| ATE156158T1 (de) | 1992-04-14 | 1997-08-15 | Cornell Res Foundation Inc | Makromoleküle auf basis von dendritischen polymeren und verfahren zur herstellung |
| US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
| US5741803A (en) | 1992-09-05 | 1998-04-21 | Smithkline Beecham Plc | Substituted thiazolidinedionle derivatives |
| ES2133158T3 (es) | 1993-01-19 | 1999-09-01 | Warner Lambert Co | Formulacion ci-981 oral, estable y proceso de preparacion del mismo. |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| FR2731710B1 (fr) | 1995-03-14 | 1997-04-30 | Rhone Poulenc Rorer Sa | Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| TW438587B (en) | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| BR9609872A (pt) | 1995-07-17 | 1999-03-23 | Warner Lambert Co | Hemi sal de cálcio de ácido (R-(R*R*)]-2-(4-fluorfenil-)-beta delta-diidróxi-5-(1-metiletil)-3-fenil-4- [(fenilamino) carbonil]-1H- pirrol-1heptanóico (atorvasta-tina)c ristalino |
| CA2236982C (en) * | 1995-11-09 | 2010-07-27 | The Government Of The United States Of America Represented By The Secretary Of The Department Of Health And Human Services | The use of lecithin-cholesterol acyltransferase (lcat) in the treatment of atherosclerosis |
| CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| FR2758459B1 (fr) | 1997-01-17 | 1999-05-07 | Pharma Pass | Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation |
| EP0973914B1 (de) * | 1997-04-11 | 2006-12-13 | Takeda Pharmaceutical Company Limited | Proteine mit lecithin-cholesterin acetyltransferase-ähnlicher aktivität, deren herstellung und verwendung |
| US6692909B1 (en) * | 1998-04-01 | 2004-02-17 | Whitehead Institute For Biomedical Research | Coding sequence polymorphisms in vascular pathology genes |
| DE69818444T2 (de) | 1998-07-15 | 2004-05-06 | Merck Santé | Tabletten enthaltend eine Kombination von Glibenclamid und Metformin |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| ATE309818T1 (de) | 2000-03-08 | 2005-12-15 | Novo Nordisk As | Senkung des serum cholesterols |
| US6596544B1 (en) * | 2000-03-31 | 2003-07-22 | The Regents Of The University Of California | Functional assay of high-density lipoprotein |
| MXPA04011312A (es) * | 2002-05-17 | 2005-02-14 | Esperion Therapeutics Inc | Metodo para el tratamiento de desordenes dislipidemicos. |
| JP2006509722A (ja) * | 2002-07-03 | 2006-03-23 | エスペリオン セラピューティクス,インコーポレイテッド | 脂質代謝異常を治療するためのパンテチン含有組成物 |
| CA2497794A1 (en) | 2002-09-06 | 2004-03-18 | Bayer Pharmaceuticals Corporation | Modified glp-1 receptor agonists and their pharmacological methods of use |
| WO2004094471A2 (en) | 2003-04-22 | 2004-11-04 | Avanir Pharmaceuticals | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia |
| WO2004103310A2 (en) * | 2003-05-20 | 2004-12-02 | New England Medical Center Hospitals, Inc. | Methods and compositions for the treatment of metabolic disorders |
-
2007
- 2007-06-26 CA CA2787343A patent/CA2787343C/en active Active
- 2007-06-26 EP EP07796488A patent/EP2037928B1/de active Active
- 2007-06-26 CA CA2654661A patent/CA2654661C/en active Active
- 2007-06-26 WO PCT/US2007/014873 patent/WO2008002591A2/en not_active Ceased
- 2007-06-26 ES ES07796488T patent/ES2376396T3/es active Active
- 2007-06-26 US US11/823,251 patent/US20080096900A1/en not_active Abandoned
- 2007-06-26 AT AT07796488T patent/ATE540681T1/de active
- 2007-06-26 EP EP11008409A patent/EP2452683A3/de not_active Withdrawn
- 2007-06-26 AU AU2007265475A patent/AU2007265475B2/en active Active
-
2011
- 2011-04-14 US US13/087,261 patent/US8426358B2/en active Active
-
2013
- 2013-03-26 US US13/851,019 patent/US20130273024A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20110206652A1 (en) | 2011-08-25 |
| US20130273024A1 (en) | 2013-10-17 |
| CA2787343C (en) | 2016-08-02 |
| WO2008002591A2 (en) | 2008-01-03 |
| US20080096900A1 (en) | 2008-04-24 |
| EP2037928B1 (de) | 2012-01-11 |
| WO2008002591A3 (en) | 2008-05-08 |
| CA2654661A1 (en) | 2008-01-03 |
| EP2037928A2 (de) | 2009-03-25 |
| AU2007265475A1 (en) | 2008-01-03 |
| US8426358B2 (en) | 2013-04-23 |
| EP2452683A3 (de) | 2012-08-22 |
| CA2787343A1 (en) | 2008-01-03 |
| ES2376396T3 (es) | 2012-03-13 |
| EP2452683A2 (de) | 2012-05-16 |
| CA2654661C (en) | 2012-10-23 |
| AU2007265475B2 (en) | 2010-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008002591A3 (en) | Methods for treating atherosclerosis | |
| DE602005011656D1 (de) | Verfahren zur behandlung von dickdarmkrebs mit botulinum neurotoxin | |
| DE602006019753D1 (de) | Verfahren und gerät zur behandlung von aneurysmen der a. thoracica | |
| ATE489955T1 (de) | Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten | |
| DE602006018354D1 (de) | Verfahren zur behandlung von abnormalem zellwachstum | |
| EP1934025A4 (de) | Zusammensetzung zur behandlung von holz, verfahren zur behandlung von holz und holzprodukt | |
| DE602007006479D1 (de) | Verfahren und vorrichtungen zur behandlung von mehreren bohrlochintervallen | |
| EP2046993A4 (de) | Rna-interferenzzusammensetzungen und verfahren zur behandlung von morbus huntington | |
| WO2008115469A3 (en) | Role of hedgehog signaling in atherosclerosis and cardiovascular disease | |
| DE602007012133D1 (de) | Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten | |
| DE602005008970D1 (de) | Verfahren und zusammensetzungen zur behandlung von augenerkrankungen mit retinyl-derivaten | |
| EP2141989A4 (de) | Zusammensetzungen und verfahren zur vorbeugung und behandlung von suchtkrankheiten | |
| EP2054047A4 (de) | Verfahren zur behandlung von akutem akustischem trauma | |
| MY159075A (en) | Modified lecithin-cholesterol acyltransferase enzymes | |
| EP2046366A4 (de) | Verfahren zur behandlung von altersbedingter makuladegeneration | |
| EP2049140A4 (de) | Kit und verfahren zur behandlung der bandscheiben | |
| DE602007001518D1 (de) | Verfahren zur Behandlung von Beton | |
| EP2069391A4 (de) | Zusammensetzungen und verfahren zur behandlung oder prävention von augenleiden | |
| ATE435026T1 (de) | Verfahren zur prävention und behandlung von diabetes mit neurturin | |
| EP2124991A4 (de) | Pharmazeutische zusammensetzungen und verfahren zur behandlung von erektiler dysfunktion | |
| ATE411803T1 (de) | Verfahren zur behandlung von schwerer herzinsuffizienz und medikament dafür | |
| EP1948675A4 (de) | Verfahren und zusammensetzungen zur behandlung von marfan-syndrom und verwandten erkrankungen | |
| EP2037736A4 (de) | Verfahren zur behandlung von zystennierenerkrankungen | |
| DE602006015182D1 (de) | Zusammensetzung und verfahren zur kontrolle von insekten | |
| DE602005010649D1 (de) | Server, Serversystem und Verfahren zur Zustellung von E-mails |